Korea Aesthetic Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF KOREA AESTHETIC MARKET 12
1.4 LIMITATIONS 14
1.5 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 CURRENCY AND PRICING 17
2.5 DBMR TRIPOD DATA VALIDATION MODEL 18
2.6 MULTIVARIATE MODELLING 21
2.7 APPLICATION LIFELINE CURVE 21
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 22
2.9 DBMR MARKET POSITION GRID 23
2.10 MARKET APPLICATION COVERAGE GRID 24
2.11 VENDOR SHARE ANALYSIS 25
2.12 SECONDARY SOURCES 25
2.13 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30
4.1 PESTEL'S MODEL 31
4.2 PORTER'S FIVE FORCES MODEL 32
5 KOREA AESTHETIC MARKET: REGULATORY FRAMEWORK 33
5.1 COMPETENT REQUIREMENTS TO PERFORM AESTHETIC PROCEDURES 34
5.2 REGULATION OF THE BEAUTY DOMAIN FOR PERFORMING AESTHETIC SERVICES 34
5.3 REGULATION OF COSMETICS-RELATED MEDICAL DEVICES 34
5.4 REGULATION OF AMBULATORY AMENITIES WHERE AESTHETIC PROCEDURES ARE PERFORMED 34
5.5 PROTECTION OF INDIVIDUALS UNDERGOING AESTHETIC PROCEDURE 35
6 SUMMARY WRITE UP (KOREA) 36
6.1 OVERVIEW 36
7 MARKET OVERVIEW 37
7.1 DRIVERS 39
7.1.1 LESSER COST OF TREATMENT FOR MEDICAL AESTHETICS AS COMPARED TO OTHER COUNTRIES 39
7.1.2 BELIEF AND TRENDS OF AESTHETIC SURGERY IN SOUTH KOREAN YOUNG ADULTS 39
7.1.3 RISE IN MEDICAL TOURISM IN KOREA 40
7.1.4 INCREASING AWARENESS ABOUT MEDICAL AESTHETICS 41
7.1.5 INCREASED USE OF MINIMALLY INVASIVE PROCEDURES 42
7.2 RESTRAINTS 42
7.2.1 PRESENCE OF UNLICENSED DERMATOLOGISTS 42
7.2.2 SOCIAL STIGMA 43
7.2.3 INADEQUATE REIMBURSEMENT DEVELOPMENT 43
7.3 OPPORTUNITIES 44
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 44
7.3.2 INCREASING RESEARCH AND DEVELOPMENT 44
7.3.3 TECHNOLOGICAL ADVANCEMENTS 45
7.3.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 45
7.4 CHALLENGES 46
7.4.1 LACK OF SKILLED EXPERTISE 46
7.4.2 SIDE EFFECTS ASSOCIATED WITH USE OF DERMAL FILLERS 46
7.4.3 STRINGENT PRODUCT APPROVALS 47
8 IMPACT OF COVID-19 ON KOREA AESTHETIC MARKET 48
8.1 PRICE IMPACT 48
8.2 IMPACT ON DEMAND 48
8.3 IMPACT ON SUPPLY CHAIN 49
8.4 STRATEGIC DECISIONS BY MANUFACTURER/SERVICE PROVIDER 49
8.5 CONCLUSION 50
9 KOREA AESTHETIC MARKET, BY DEVICES 51
9.1 OVERVIEW 52
9.2 NON ENERGY BASED AESTHETIC DEVICES 55
9.2.1 BOTULINUM TOXIN 55
9.2.2 DERMAL FILLERS AND AESTHETIC THREADS 55
9.2.3 IMPLANTS 56
9.2.4 MICRODERMABRASION 56
9.2.5 CHEMICAL PEELS 56
9.2.6 OTHERS 56
9.3 ENERGY BASED AESTHETIC DEVICES 56
9.3.1 LASER BASED AESTHETIC DEVICES 57
9.3.2 ULTRASOUND AESTHETIC DEVICES 57
9.3.3 RADIOFREQUENCY (RF) BASED AESTHETIC DEVICES 57
9.3.4 LIGHT BASED AESTHETIC DEVICES 57
9.3.5 OTHERS 57
10 KOREA AESTHETIC MARKET, BY APPLICATION 58
10.1 OVERVIEW 59
10.2 NON-SURGICAL 62
10.2.1 BODY CONTOURING 62
10.2.2 NON INVASIVE FAT REDUCTION 62
10.2.3 SKIN TIGHTENING 62
10.2.4 ACNE TREATMENTS 62
10.2.5 HAIR REMOVAL 63
10.2.6 TATTOO REMOVAL 63
10.2.7 OTHERS 63
10.3 SURGICAL 63
10.3.1 FACE & HEAD SURGERY 64
10.3.1.1 FACEL LIFT 64
10.3.1.2 BROW LIFT 64
10.3.1.3 FACIAL BONE CONTOURING 64
10.3.1.4 NECK LIFT 64
10.3.1.5 OTHERS 64
10.3.2 BREAST SURGERY 65
10.3.2.1 BREAST AUGMENTATION 65
10.3.2.2 BREAST LIFT 65
10.3.3 BODY & EXTREMITIES 65
10.3.3.1 LIPOSUCTION 66
10.3.3.2 LOWER BODY LIFT 66
10.3.3.3 THIGH LIFT 66
10.3.3.4 UPPER ARM LIFT 66
10.3.3.5 OTHER 66
11 KOREA AESTHETIC MARKET, BY BRANDS 67
11.1 OVERVIEW 68
11.2 BOTULINUM TOXIN 71
11.2.1 NABOTA 72
11.2.2 BOTOX 72
11.2.3 BOTULAX 72
11.2.4 MEDITOXIN 72
11.2.5 XEOMIN 72
11.2.6 OTHERS 72
11.3 DERMAL FILLER 72
11.3.1 JUVEDERM 73
11.3.2 RESTYLANE 73
11.3.3 BELOTERO 73
11.3.4 CHAEUM 73
11.3.5 OTHERS 73
11.4 SKIN LIFTING 73
11.4.1 INMODE 74
11.4.2 ULTHERA 74
11.4.3 ULTRAFORMER III 74
11.4.4 THERMAGE 74
11.4.5 OTHER 74
11.5 OTHERS 75
12 KOREA AESTHETIC MARKET, BY GENDER 76
12.1 OVERVIEW 77
12.2 FEMALE 80
12.3 MALE 81
13 KOREA AESTHETIC MARKET, BY END USER 82
13.1 OVERVIEW 83
13.2 DERMATOLOGY CENTERS 86
13.3 HOSPITALS 86
13.4 SPECIALTY CLINICS 87
13.5 MEDICAL SPAS & BEAUTY CENTERS 87
13.6 OTHERS 88
14 KOREA AESTHETIC MARKET, BY DISTRIBUTION CHANNEL 89
14.1 OVERVIEW 90
14.2 DIRECT TENDER 93
14.3 RETAIL SALES 93
15 KOREA AESTHETIC MARKET: COMPANY LANDSCAPE 94
16 SWOT ANALYSIS 95
17 COMPANY PROFILE 96
17.1 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 96
17.1.1 COMPANY SNAPSHOT 96
17.1.2 REVENUE ANALYSIS 96
17.1.3 PRODUCT PORTFOLIO 97
17.1.4 RECENT DEVELOPMENTS 98
17.2 DAEWOONG PHARMACEUTICAL CO.,LTD. 99
17.2.1 COMPANY SNAPSHOT 99
17.2.2 REVENUE ANALYSIS 99
17.2.3 PRODUCT PORTFOLIO 100
17.2.4 RECENT DEVELOPMENTS 100
17.3 GALDERMA 102
17.3.1 COMPANY SNAPSHOT 102
17.3.2 PRODUCT PORTFOLIO 102
17.3.3 RECENT DEVELOPMENTS 103
17.4 CYNOSURE, INC. (A SUBSIDIARY OF HOLOGIC, INC.) 104
17.4.1 COMPANY SNAPSHOT 104
17.4.2 REVENUE ANALYSIS 104
17.4.3 PRODUCT PORTFOLIO 105
17.4.4 RECENT DEVELOPMENTS 106
17.5 MERZ PHARMA 107
17.5.1 COMPANY SNAPSHOT 107
17.5.2 PRODUCT PORTFOLIO 107
17.5.3 RECENT DEVELOPMENTS 108
17.6 AMIINC 110
17.6.1 COMPANY SNAPSHOT 110
17.6.2 PRODUCT PORTFOLIO 110
17.6.3 RECENT DEVELOPMENTS 111
17.7 BAUSCH HEALTH COMPANIES INC. 112
17.7.1 COMPANY SNAPSHOT 112
17.7.2 REVENUE ANALYSIS 112
17.7.3 PRODUCT PORTFOLIO 113
17.7.4 RECENT DEVELOPMENTS 113
17.8 BISON MEDICAL 114
17.8.1 COMPANY SNAPSHOT 114
17.8.2 PRODUCT PORTFOLIO 114
17.8.3 RECENT DEVELOPMENTS 115
17.9 BLUECORE COMPANY 117
17.9.1 COMPANY SNAPSHOT 117
17.9.2 PRODUCT PORTFOLIO 117
17.9.3 RECENT DEVELOPMENTS 117
17.10 CANDELA MEDICAL 119
17.10.1 COMPANY SNAPSHOT 119
17.10.2 PRODUCT PORTFOLIO 119
17.10.3 RECENT DEVELOPMENTS 120
17.11 CLASSYS INC. 121
17.11.1 COMPANY SNAPSHOT 121
17.11.2 PRODUCT PORTFOLIO 121
17.11.3 RECENT DEVELOPMENTS 122
17.12 INMODE GROUP 123
17.12.1 COMPANY SNAPSHOT 123
17.12.2 REVENUE ANALYSIS 124
17.12.3 PRODUCT PORTFOLIO 124
17.12.4 RECENT DEVELOPMENTS 125
17.13 HIRONIC CO., LTD. 126
17.13.1 COMPANY SNAPSHOT 126
17.13.2 PRODUCT PORTFOLIO 126
17.13.3 RECENT DEVELOPMENTS 127
17.14 HUGEL, INC. 128
17.14.1 COMPANY SNAPSHOT 128
17.14.2 REVENUE ANALYSIS 128
17.14.3 PRODUCT PORTFOLIO 129
17.14.4 RECENT DEVELOPMENTS 129
17.15 MEDYTOX 130
17.15.1 COMPANY SNAPSHOT 130
17.15.2 PRODUCT PORTFOLIO 130
17.15.3 RECENT DEVELOPMENT 131
17.16 UNION MEDICAL 132
17.16.1 COMPANY SNAPSHOT 132
17.16.2 PRODUCT PORTFOLIO 132
17.16.3 RECENT DEVELOPMENTS 133
17.17 WEERO 134
17.17.1 COMPANY SNAPSHOT 134
17.17.2 PRODUCT PORTFOLIO 134
17.17.3 RECENT DEVELOPMENTS 135
18 QUESTIONNAIRE 136
19 RELATED REPORTS 139